Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Novartis AG (NOVN) Receives a Hold from UBS

Tipranks - Tipranks - Tue Mar 24, 9:42AM CDT

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novartis AG, with a price target of CHF116.00.

Claim 30% Off TipRanks Premium

Weston covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, Novo Nordisk, and Roche Holding AG. According to TipRanks, Weston has an average return of 10.2% and a 69.00% success rate on recommended stocks.

In addition to UBS, Novartis AG also received a Hold from Barclays’s James Gordon CFA in a report issued on March 20. However, today, Bank of America Securities reiterated a Buy rating on Novartis AG (Six Swiss: NOVN).

See Insiders’ Hot Stocks on TipRanks >>

Based on Novartis AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of CHF13.44 billion and a net profit of CHF2.43 billion. In comparison, last year the company earned a revenue of CHF13.56 billion and had a net profit of CHF2.82 billion

Read More on CH:NOVN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).